新型前房人工晶状体植入的临床观察

A new anterior chamber intraocular lens implantation

目的:探讨新型前房型人工晶状体I期或II期植入的临床效果及安全性。方法:对38例(39眼)无条件植入后房型人工晶状体者,植入新型前房型人工晶状体并对其术后视力及并发症进行观察分析。结果:术后1wk,脱盲率及脱残率分别为92%及64%,并发症较少。结论:新型前房型人工晶状体植入是安全有效的,可作为不能植入后房型人工晶状体的替代术式,但必须随访以及时发现及处理远期并发症。

AIM: To examine the clinical effect and safety of a new anterior chamber intraocular lens (AC-IOL) implantation.· METHODS: The postoperative vision and the complications of AC-IOL implanation in 39 eyes of 38 patients who cannot undergo posterior chamber lens (PC-IOL) implantation were observed and analysed.· RESULTS: The restoring light (vision≥0.05) rate and the rehabiliation (vision≥0.3) rate of the patients at the first week after operation were 92.3% and 64.1% respectively, with a few complications.· CONCLUSION: Being safe and effective, AC-IOL implantation can substitute for PC-IOL implantation in cases who cannot undergo PC-IOL implantation. But follow-up is necessary to find out and treat long-term complications in time.